Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2010-04-12

Clinical Trial Update: A Long-term Safety Study of Once-daily Travatan [Phase 3]

View source ↗

Summary

Long-term safety results from a Phase 3 study evaluating once-daily Travatan (latanoprost) in open-angle glaucoma and ocular hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Travatan (travoprost)

Snippet

Sponsor: Alcon Research | Conditions: Glaucoma, Open-angle, Ocular Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2010-04-12